Last updated: September 7, 2026
XGEVA generated approximately $2.1 billion in annual sales for Amgen in 2024, but its growth profile is changing. The product has lost U.S. reference-product exclusivity, and the FDA approved denosumab biosimilars in 2025. XGEVA remains commercially important because of its use in oncology and its high treatment value, but biosimilar entry, payer substitution, and competition from generic zoledronic acid are expected to pressure price and volume.
What is XGEVA and how does it generate revenue?
XGEVA is denosumab, a fully human monoclonal antibody that binds RANK ligand and inhibits osteoclast-mediated bone resorption. Amgen markets it as a 120 mg subcutaneous injection administered every four weeks for most oncology indications.
The FDA approved XGEVA in November 2010. Its approved uses include:
- Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors
- Treatment of adults and skeletally mature adolescents with unresectable or metastatic giant cell tumor of bone
- Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy
XGEVA is distinct from Prolia, which is also denosumab but is administered at a lower dose and on a less frequent schedule for osteoporosis and related indications. XGEVA has a substantially higher annual treatment cost and greater exposure to oncology specialty distribution and hospital purchasing.
| Product |
Active ingredient |
Typical dose |
Main market |
Amgen 2024 sales |
| XGEVA |
Denosumab |
120 mg every 4 weeks |
Oncology and giant cell tumor |
Approximately $2.1 billion |
| Prolia |
Denosumab |
60 mg every 6 months |
Osteoporosis |
Approximately $4.0 billion |
Amgen reported worldwide XGEVA sales of roughly $2.1 billion in 2024, compared with approximately $2.1 billion in 2023. The relative stability before biosimilar entry reflects continued oncology demand, pricing, and the absence of an established U.S. biosimilar competitor during most of the period. [1]
How has XGEVA’s financial trajectory changed?
XGEVA’s financial trajectory has moved through three phases: rapid adoption, mature-brand stability, and impending biosimilar erosion.
Revenue trajectory
| Year |
Approximate XGEVA sales |
Commercial interpretation |
| 2020 |
$1.9 billion |
Mature oncology franchise |
| 2021 |
$2.0 billion |
Continued demand and price contribution |
| 2022 |
$2.1 billion |
Stable high-value biologic sales |
| 2023 |
$2.1 billion |
Mature product with limited unit growth |
| 2024 |
$2.1 billion |
Stable revenue before U.S. biosimilar launch |
The product has not shown the growth profile of a newer oncology biologic. Revenue has largely depended on treatment persistence, label breadth, pricing, and Amgen’s commercial infrastructure. The largest financial risk is not an immediate collapse in demand but the gradual loss of net price as payers introduce biosimilar controls.
Biosimilar erosion may initially be slower than erosion for small-molecule products because XGEVA is administered in oncology clinics, requires cold-chain handling, and is often purchased through physician offices, hospitals, and specialty distributors. Those channels create operational friction around product switching. Price competition will still increase as oncology practices and payers gain access to interchangeable or therapeutically substitutable denosumab products.
When did XGEVA lose exclusivity?
XGEVA’s U.S. reference-product exclusivity expired in 2022. The FDA grants an approved biologic 12 years of reference-product exclusivity under the Biologics Price Competition and Innovation Act. Because XGEVA was approved on November 18, 2010, its 12-year exclusivity period ended in November 2022. [2]
Reference-product exclusivity is separate from patent protection. Expiration of the 12-year period permits FDA approval of biosimilars, but a biosimilar applicant must still address applicable patents, patent litigation, regulatory requirements, and commercial launch restrictions.
XGEVA has entered the post-exclusivity period with revenue intact because biosimilar approval and launch timing were delayed by patent disputes and settlement arrangements.
What is the FDA regulatory status of XGEVA biosimilars?
The FDA approved two denosumab biosimilar products from Sandoz in March 2025:
- Jubbonti, denosumab-bbdz, referencing Prolia
- Wyost, denosumab-bbdz, referencing XGEVA
The products contain the same active ingredient, denosumab-bbdz, but are marketed under separate brand names because they reference different Amgen products and dosing regimens. FDA approval covered the relevant indications for the reference products, subject to the biosimilar approval framework. [3]
The approvals marked the first U.S. biosimilar entry directed at the denosumab franchise. Sandoz stated that the products were expected to launch under an agreement with Amgen no later than May 31, 2025. [4]
The FDA approval does not mean that every XGEVA patient will switch immediately. Uptake will depend on:
- Whether payers place the biosimilar on preferred oncology formularies
- The availability of clinic-level reimbursement incentives
- Distributor stocking and contracting
- Physician confidence in switching
- Whether the product receives or obtains interchangeable status
- Differences between medical-benefit and pharmacy-benefit purchasing
What patents protect XGEVA?
XGEVA’s protection has relied on patents covering denosumab antibodies, anti-RANKL activity, therapeutic uses, formulations, and manufacturing-related subject matter. The relevant portfolio is not equivalent to an Orange Book listing because XGEVA is a biologic.
Does XGEVA have Orange Book patents?
No. XGEVA is licensed under the Public Health Service Act as a biologic, not approved under the Federal Food, Drug, and Cosmetic Act as a small-molecule drug. It therefore does not have an Orange Book patent listing in the conventional Hatch-Waxman format.
The relevant regulatory reference is the FDA Purple Book, while patent disputes proceed under the BPCIA framework and conventional federal patent litigation. [5]
What types of patents affect denosumab competition?
The principal categories are:
- Composition-of-matter patents. These cover anti-RANKL antibodies or antibody sequences and related binding properties.
- Method-of-use patents. These cover treatment or prevention of skeletal-related events, giant cell tumor of bone, malignancy-associated hypercalcemia, and other clinical uses.
- Formulation patents. These may cover concentration, stabilizers, excipients, pH, container systems, or storage conditions.
- Manufacturing patents. These may cover cell culture, purification, formulation, fill-finish, or process controls.
- Regimen and dosing patents. These may cover administration schedules or patient subsets.
The commercial value of any remaining patent depends on claim scope, validity, enforceability, expiration, and whether a biosimilar can launch with a label that omits the protected indication or method.
Amgen’s practical protection has been stronger than a single patent expiration date. The company has used a portfolio approach combined with BPCIA litigation and settlement negotiations. The underlying antibody and early platform patents are old relative to XGEVA’s 2010 approval, making later patents and regulatory exclusivity more important to current commercial defense.
Which companies are challenging XGEVA?
Sandoz is the first company with FDA-approved U.S. denosumab biosimilars. Its products create direct competition for both the XGEVA and Prolia segments.
Other companies have pursued or publicly disclosed denosumab biosimilar programs in the United States and Europe, including firms with oncology and immunology biosimilar capabilities. The competitive field can change by jurisdiction because approval dates, patent settlements, and launch rights differ between the United States, European Union, and other markets.
The most important near-term competitive threat is Sandoz because it has an FDA-approved product, a defined U.S. launch arrangement, and a portfolio that addresses both denosumab reference products.
What patent litigation affects XGEVA?
Amgen brought patent litigation against Sandoz after Sandoz pursued U.S. approval for denosumab biosimilars. The dispute involved Amgen’s denosumab patent estate and the BPCIA patent-exchange process.
The parties later reached an agreement permitting Sandoz to launch its denosumab biosimilars in the United States by May 31, 2025, subject to the terms of the settlement. The arrangement reduced the risk of an immediate injunction while setting a commercially meaningful entry date. [4]
The settlement has two financial consequences:
- Amgen retained a period of additional market protection after FDA approval.
- Sandoz received a defined path to launch rather than waiting for every patent dispute to reach final judgment.
The agreement does not eliminate all possible patent disputes involving other biosimilar applicants or later-filed patents. It also does not prevent Amgen from defending manufacturing, formulation, or use patents where legally available.
How strong is the XGEVA patent estate?
XGEVA’s patent estate is best characterized as commercially meaningful but materially weakened by the age of the product and the arrival of approved biosimilars.
Strengths
- High-value oncology indications
- Complex biologic manufacturing
- Multiple potential patent categories
- Clinic-administered product with operational switching barriers
- Amgen’s ability to bundle XGEVA and Prolia commercial expertise
- Potential use of indication-specific labeling strategies
Weaknesses
- U.S. biologic exclusivity expired in 2022
- The core molecule is established and clinically well characterized
- FDA-approved biosimilar competition now exists
- Generic zoledronic acid provides a low-cost alternative in several settings
- Oncology payers have experience with biosimilar adoption
- Later patents may face validity and obviousness challenges
The product’s protection is therefore shifting from exclusivity-based defense to lifecycle management, contracting, manufacturing scale, and physician-channel retention.
How does XGEVA compare with competing bone-modifying agents?
The main competitive comparison is between XGEVA and zoledronic acid, a generic intravenous bisphosphonate sold under the former Zometa brand and generic names.
| Attribute |
XGEVA |
Zoledronic acid |
| Mechanism |
RANKL inhibition |
Bisphosphonate-mediated osteoclast inhibition |
| Administration |
Subcutaneous injection |
Intravenous infusion |
| Typical oncology schedule |
Every 4 weeks, with indication-specific variation |
Usually every 3 to 4 weeks initially, then extended in some patients |
| Patent status |
Biologic with biosimilar competition |
Generic competition |
| Renal dosing concerns |
No renal dose adjustment, but hypocalcemia risk |
Renal monitoring and dose limitations are important |
| Acquisition cost |
High |
Substantially lower |
| Commercial channel |
Oncology clinic and specialty distribution |
Hospital and infusion-center purchasing |
| Key advantage |
Efficacy and administration profile in selected patients |
Low cost and established use |
XGEVA has clinical and operational advantages in patients where renal impairment affects bisphosphonate selection. Zoledronic acid remains a major pricing constraint because payers can use it as a reference for cost-effective bone protection.
Prolia is not a direct substitute for XGEVA in oncology dosing. Its lower dose and six-month schedule address osteoporosis and bone-loss indications, not the full XGEVA oncology regimen.
What generic and biosimilar launch scenarios exist for XGEVA?
Three scenarios are commercially relevant.
Gradual biosimilar adoption
In this scenario, Sandoz gains preferred formulary placement but switching occurs mainly in newly treated patients. Existing patients remain on XGEVA because of physician preference, established clinic workflows, or reimbursement contracts. Amgen’s revenue declines gradually through lower net price and slower new-patient starts.
Accelerated payer substitution
Payers designate denosumab-bbdz as preferred and require prior authorization for XGEVA. Oncology practices face economic pressure to use the biosimilar. This scenario produces faster price compression and higher conversion among treatment-naive patients.
Limited biosimilar penetration
XGEVA retains meaningful share because of contracting, clinical familiarity, supply reliability, or product-level reimbursement advantages. Revenue declines primarily through discounts rather than large unit losses. This would preserve more of Amgen’s oncology cash flow but would not prevent long-term erosion.
A traditional generic launch scenario does not apply to XGEVA because denosumab is a biologic. The relevant competitors are biosimilars, not ANDA-approved generic injections.
What manufacturing and IP barriers protect XGEVA?
Manufacturing remains a meaningful barrier even after patent expiry. Denosumab requires mammalian-cell production, purification, viral safety controls, analytical comparability, sterile fill-finish, and cold-chain distribution. Biosimilar applicants must demonstrate high similarity through analytical, pharmacokinetic, immunogenicity, and clinical evidence.
Manufacturing barriers support a slower competitive ramp than in small-molecule markets. They do not preserve monopoly pricing once multiple suppliers can manufacture at scale. The commercial importance of supply reliability may be high because oncology clinics are sensitive to treatment interruptions and product availability.
Amgen also has scale advantages in:
- Global biologics manufacturing
- Specialty distribution
- Medical-benefit contracting
- Oncology account management
- Safety monitoring
- Support services and reimbursement assistance
These advantages can delay share loss but cannot permanently prevent biosimilar substitution.
What is the geographic coverage and international outlook?
The United States is the highest-value market for XGEVA and the principal source of near-term biosimilar risk. European markets generally adopt biosimilars more rapidly because of centralized procurement, national reimbursement systems, and hospital tendering.
XGEVA’s international revenue is exposed to:
- National tender pricing
- Reference pricing
- Hospital substitution policies
- Local biosimilar approvals
- Patent and supplementary protection certificate status
- Differences in oncology treatment guidelines
Amgen may preserve higher prices in markets with slower biosimilar uptake, but international net pricing is generally more vulnerable to procurement pressure than U.S. branded oncology pricing.
What is the revenue exposure from XGEVA?
XGEVA represents roughly 6% of Amgen’s annual revenue based on 2024 product sales and total company revenue of approximately $33.4 billion. [1] That percentage is material but manageable within Amgen’s broader portfolio, which includes Enbrel, Otezla, Repatha, Prolia, Evenity, Kyprolis, and newer products acquired or developed through its pipeline and Horizon Therapeutics transaction.
The larger strategic issue is the combined denosumab franchise. Prolia is more valuable than XGEVA on a revenue basis, and the same biosimilar platform can affect both products. A successful denosumab biosimilar can therefore create commercial pressure across two major Amgen brands.
What is the outlook for XGEVA after biosimilar entry?
XGEVA should remain a multibillion-dollar product in the near term, but its long-term revenue is likely to decline as biosimilar contracting expands. The pace will depend more on payer policy and clinic economics than on clinical obsolescence.
The most likely trajectory is:
- Stable or modestly declining sales during the initial launch period
- Increasing discounts and formulary pressure after biosimilar availability
- Greater erosion in new-patient starts than in established patients
- Continued use in renal-impaired patients and selected oncology populations
- Long-term pressure from both denosumab biosimilars and generic zoledronic acid
Amgen’s strongest defenses are clinical familiarity, supply reliability, oncology infrastructure, and the ability to manage XGEVA and Prolia as a coordinated franchise. Its weakest defense is the absence of remaining reference-product exclusivity in the United States.
Key Takeaways
- XGEVA is Amgen’s high-dose oncology formulation of denosumab.
- 2024 sales were approximately $2.1 billion.
- U.S. biologic exclusivity expired in November 2022.
- XGEVA has no conventional Orange Book patent listing because it is a biologic.
- Sandoz received FDA approval for Jubbonti and Wyost in March 2025.
- The Sandoz-Amgen settlement allowed U.S. launch by May 31, 2025.
- Biosimilar risk affects both XGEVA and the larger Prolia franchise.
- Generic zoledronic acid remains the principal low-cost clinical competitor.
- Manufacturing complexity will slow, but not prevent, denosumab price erosion.
- XGEVA is likely to remain financially significant while transitioning from protected biologic to mature specialty product.
FAQs About XGEVA Market Competition and Exclusivity
Is XGEVA the same drug as Prolia?
Yes. Both contain denosumab, but they have different doses, schedules, FDA indications, packaging, and commercial positioning. XGEVA is primarily an oncology product, while Prolia is used mainly for osteoporosis and related bone-loss conditions.
Can a denosumab biosimilar automatically replace XGEVA?
No. FDA biosimilarity does not automatically create pharmacy-level substitution. Substitution depends on interchangeability status, state law, payer policy, medical-benefit rules, and physician or clinic procedures.
Is XGEVA still patent protected after 2025?
Potentially, depending on the specific patent, claim, jurisdiction, and indication. The product’s core U.S. exclusivity has expired, but later patents may cover formulations, methods of use, dosing, or manufacturing.
Will XGEVA lose more revenue than Prolia from biosimilars?
Not necessarily. XGEVA faces concentrated oncology purchasing and direct competition from zoledronic acid, which may accelerate switching. Prolia has greater revenue but a different prescribing environment and may experience slower or faster erosion depending on payer policy.
What is the main investment risk for XGEVA?
The main risk is net-price erosion after denosumab biosimilar entry. Volume loss, payer-mandated switching, oncology clinic contracting, and competition from generic zoledronic acid will determine the size and speed of the decline.
References
- Amgen Inc. (2025). 2024 annual report. https://www.amgen.com
- U.S. Food and Drug Administration. (2024). Reference product exclusivity and biosimilar products under the Biologics Price Competition and Innovation Act. https://www.fda.gov
- U.S. Food and Drug Administration. (2025). FDA approves denosumab biosimilars Jubbonti and Wyost. https://www.fda.gov
- Sandoz Group AG. (2025). Sandoz announces U.S. launch plans for denosumab biosimilars. https://www.sandoz.com
- U.S. Food and Drug Administration. (2025). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
